SLN.L Regulatory News (SLN)

30 July 2015

Silence Therapeutics plc

("Silence" or "the Company")

Interim Board Change

Silence Therapeutics plc, AIM: SLN, a leader in the development and delivery of novel RNA therapeutics, announces that Ali Mortazavi, Chief Executive of Silence, has taken a temporary compassionate leave of absence for approximately two months from his role within the Company due to an acute illness in his family. The Company's Non-Executive Chairman, Dr. Alastair Riddell, will take on the role of Executive Chairman on an interim basis, until Ali Mortazavi's return.

Alastair Riddell joined the Board of Silence in November 2013 and was appointed Non-Executive Chairman in January 2015. He has 32 years' experience in the biopharmaceutical sector, including 15 years as CEO and Chairman of several UK biotechs. As CEO of Pharmagene, he completed a successful flotation on the UK main list and as CEO of Paradigm Therapeutics executed a trade sale to Takeda.

Enquiries:

Notes to Editors

About Silence Therapeutics (www.silence-therapeutics.com)

Silence Therapeutics is a leading RNA therapeutics company. It has developed proprietary modifications to improve the robustness of RNA sequences together with advanced liposomal chemistries to enhance the delivery of its therapeutics. Its technology can selectively silence or replace the expression of any gene in the genome, modulating expression up as well as down in a variety of organs and cell types, in vivo. This allows the development of therapeutics for diseases with high unmet clinical need.